Device Trial Radar · NCT01574664
Evaluation of RFID Localization System for Marking and Retrieving Breast Lesions
Last checked: Nov 20, 2026Latest source record: May 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Health BeaconsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 10, 2012
Design
- Study type
- Observational
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this investigation is to obtain clinical data to show the Health Beacons Radiofrequency Identification (RFID) Localization System is safe and performs as intended as a localization device for marking and retrieving a non-palpable surgical target from the breast.
Conditions
- Non-palpable Breast Lesions
Interventions
RFID Tag (Health Beacon)Device
The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The surgical target is visualized in the removed specimen AND the RFID Tag was removed from the patient's breast.Time frame: Within 96 hours after lumpectomy
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sharp Memorial Hospital
San Diego, California
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.